bluebird bio, Inc. Stock price

Equities

BLUE

US09609G1004

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
1.44 USD +1.41% Intraday chart for bluebird bio, Inc. +3.60% +4.35%
Sales 2023 * 39.89M Sales 2024 * 137M Capitalization 278M
Net income 2023 * -196M Net income 2024 * -236M EV / Sales 2023 * 1.66 x
Net cash position 2023 * 212M Net cash position 2024 * 152M EV / Sales 2024 * 0.92 x
P/E ratio 2023 *
-0.84 x
P/E ratio 2024 *
-0.83 x
Employees 323
Yield 2023 *
-
Yield 2024 *
-
Free-Float 99.63%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.41%
1 week+3.60%
Current month+3.60%
1 month+41.18%
3 months-52.79%
6 months-54.86%
Current year+4.35%
More quotes
1 week
1.30
Extreme 1.3
1.55
1 month
1.02
Extreme 1.02
1.92
Current year
0.88
Extreme 0.879
1.92
1 year
0.88
Extreme 0.879
5.53
3 years
0.88
Extreme 0.879
35.59
5 years
0.88
Extreme 0.879
163.43
10 years
0.88
Extreme 0.879
236.17
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 15-12-31
Director of Finance/CFO 51 22-11-06
Chief Tech/Sci/R&D Officer - 21-11-30
Members of the board TitleAgeSince
Chairman 65 14-07-15
Director/Board Member 51 10-02-28
Director/Board Member 56 23-04-02
More insiders
Date Price Change Volume
24-03-18 1.44 +1.41% 7,972,233
24-03-15 1.42 +6.77% 29,308,707
24-03-14 1.33 -4.32% 4,737,846
24-03-13 1.39 +3.35% 6,041,231
24-03-12 1.345 -3.24% 7,431,337

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. It has two gene therapies: ZYNTEGLO (betibeglogene autotemcel) and SKYSONA (elivaldogene autotemcel). ZYNTEGLO is the first gene therapy for people with B-thalassemia who require regular red blood cell transfusions. SKYSONA (elivaldogene autotemcel), also known as eli-cel, is used to slow the progression of eurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). It is also developing (lovotibeglogene autotemcel), also known as lovo-cel, as a one-time treatment for patients with sickle cell disease (SCD).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
1.44 USD
Average target price
4.638 USD
Spread / Average Target
+222.10%
Consensus
  1. Stock
  2. Equities
  3. Stock bluebird bio, Inc. - Nasdaq